Home Icon

Loading, Please Wait...

Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer

1267 Days ago

Oncology executive with more than 20 years of commercial strategy and operations experience in global and emerging biopharmaceutical companies

WALTHAM, Mass., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has appointed Daniel C. Martin as Chief Commercial Officer. In this newly created role, Mr. Martin will be responsible for establishing the global strategy and leading the commercial organization at Deciphera.

“We are excited to welcome Dan to the Deciphera leadership team as we continue to build the capabilities necessary to become a fully-integrated biopharmaceutical company,” said Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera Pharmaceuticals. "Dan’s significant experience developing commercial capabilities and launching new cancer medicines will be pivotal as we plan for the potential registration and commercialization of DCC-2618 and the continued development of our clinical-stage pipeline.”

“Deciphera is committed to improving the lives of patients by addressing key mechanisms that limit the effectiveness of existing cancer treatments,” said Mr. Martin. “I look forward to joining the team and building a commercial organization focused on bringing improved treatment options to patients with cancer.”

Mr. Martin has more than 20 years of commercial experience within the biopharmaceutical industry with extensive background in oncology, including immuno-oncology. Prior to joining Deciphera, he served as Senior Vice President, Commercial at Heron Therapeutics where he built the company’s commercial organization, including establishing marketing, sales, and market access functions, and launched its oncology portfolio. Mr. Martin also served as commercial lead for Heron’s portfolio strategy and new product planning across all therapeutic areas. Before joining Heron, Mr. Martin held commercial leadership positions at Dendreon and at Amgen, where he played lead roles in multiple U.S. and global oncology launches. Earlier in his career, Mr. Martin was a management consultant with Deloitte Consulting where he advised global biopharmaceutical companies in commercial strategy and operations. Mr. Martin received his undergraduate degree with honors in economics and biology from the University of Virginia and an MBA from the Wharton School at the University of Pennsylvania.

About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the potential registration and commercialization of DCC-2618 and the continued development of our clinical-stage pipeline. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of our drug candidates, including DCC-2618, our advancement of multiple early-stage efforts, our ability to successfully demonstrate the efficacy and safety of our drug candidates, the preclinical and clinical results for our drug candidates, which may not support further development of such drug candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and other risks identified in our SEC filings, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

The Yates Network
Gina Nugent, 617-460-3579
Investor Relations:
Argot Partners
Laura Perry or Sam Martin, 212-600-1902
Laura@argotpartners.com or Sam@argotpartners.com
Deciphera Pharmaceuticals, LLC
Christopher J. Morl, 781-209-6418
Chief Business Officer

We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals? Find your City Portal